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Summary 
We have investigated the reactivity to two human histocompatibility leukocyte antigen (HLA) 
All-restricted  cytotoxic T  lymphocyte (CTL)  epitopes derived fi:om amino  acids  416-424 
(IVTDFSVIK, designated IVT) and 399-408 (AVFDRKSVAK, designated AVF) of  the Epstein- 
Barr virus (EBV) nuclear antigen (EBNA) 4. A strong predominance of CTL clones specific for 
the IVT epitope was demonstrated in polyclonal cultures generated by stimulation oflymphocytes 
from the EBV-seropositive donor BK with the autologous B95.8 virus-transformed lymphoblas- 
toid cell line (LCL). This was not due to intrinsic differences ofCTL eflaciency since clones speci- 
fic for the two epitopes lysed equally well All-positive phytohemagglutinin blasts and LCLs 
pulsed with the relevant synthetic peptide. Irrespective of the endogenous levels of  EBNA4 ex- 
pression, untreated LCLs were lysed more efficiently by the IVT-specific effectors, suggesting 
that a higher density of  All-IVT complexes is presented at the cell surface. In accordance, 10-- 
50-fold higher amounts oflVT peptides were found in high-performance liquid chromatography 
fractions of acid extracts corresponding to an abundance of about 350--12,800 IVT and 8-760 
AVF molecules per cell. Peptide-mediated competition of CTL sensitization, transport assays in 
streptolysin-O permeabilized cells, and induction of  All expression in the transporter associated 
with antigen presentation-deficient T2/A11 transfectant demonstrated that the IVT and AVF 
peptides bind with similar affinities  to A11, are translocated with equal eflSciency to the endo- 
plasmic reticulum, and form complexes of  comparable stability over a wide range of  temperature 
and pH conditions. A rapid surface tumover of  A11 molecules containing the AVF peptide was 
demonstrated in metabolically active T2/A11 cells corresponding to a half-life of,'-'3.5 as com- 
pared to ~2 h for molecules induced at 26~  in the absence of exogenous petpides and >12 h 
for IVT-containing complexes. This difference in persistence is likely to determine the repre- 
sentation of  individual class I-restricted CTL epitopes within the cell surface pool of  molecules, 
and may be an important factor contributing to their immunogenicity. 
C 
TLs  recognize short  peptides  that  are  derived from 
proteolytic degradation  of intracellular  antigens  and 
are presented at the surface of  virus-infected and tumor cells 
in association with self-MHC class I molecules (1). Antigenic 
peptides are usually 8-10 amino acids long and contain spe- 
cific consensus motit~ that allow binding to the presenting 
class  I  allele (2,  3).  Despite the  great complexity of most 
protein antigens,  and the presence in each protein of nu- 
merous peptides that may potentially bind to a given class I 
allele, T cell responses are usually focused on a limited num- 
ber ofirnmunodominant epitopes (4, 5). Several mechanisms 
may account for the generation of  this selective inmaunodom- 
inance.  In  different experimental models,  T  cell  responses 
were shown to correlate with the diiciency of generation of 
the antigenic peptide by proteolytic degradation of  native anti- 
gens (6-8), the at~fity of  binding to the relevant MHC mol- 
ecules (9-11), or the stability of the corresponding MHC- 
peptide complex (12). In addition, a selectivity based on size 
and some sequence characteristics has been demonstrated in 
the activity of the transporters associated with antigen pre- 
sentation (TAP) 1 which is likely to influence the availability 
lAbbreviations used in this paper: AVF, AVFDRKSDAK; 132m, ~2-micro- 
globulin; EBNA, Epstein-Barr virus nuclear antigen; EK, endoplasmic 
reticulum; IVT, IVTDFSVIK;  LCL,  lymphoblastoid  cell  line; TAP, trans- 
porter associated with antigen presentation. 
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lum (ER)  (13,  14). It is not clear, however, to what extent 
these in vitro parameters influence determinant selection and 
immunodommance  in  class I-restricted  CTL  responses  to 
pathogens in vivo. 
In the present investigation we have examined the issue 
of immunodominance  in the  context  of human  CTL re- 
sponses to EBV,  a  common herpesvirus  that causes infec- 
tious mononucleosis and is associated with a variety of ma- 
hgnancies of  lymphoid and epithehal cell origin (for a review 
see  reference  15).  Primary  EBV  infection  usually  occurs 
asymptomatically  in  childhood  or  adolescence  and  is  fol- 
lowed  by  the  estabhshment  of  a  hfe-long  carrier  state 
whereby the  virus persists  in latendy  infected B  lympho- 
cytes. These virus-infected cells may give rise to EBV-car- 
tying lymphoblastoid cell lines (LCL) upon in vitro culture 
of blood lymphocytes in the presence  of T  cell inhibitory 
drugs (16), and may cause lymphoprohferative disorders in 
severely immunosuppressed individuals such as organ trans- 
plant recipients and HIV patients (17, 18). CTLs play a ma- 
jor role in bruiting the prohferative potential of EBV-trans- 
formed lymphoblasts. Studies in healthy virus carriers have 
shown that EBV-specific memory CTL responses are usu- 
ally class  I  restricted  and  are directed  to the  five Epstein- 
Barr virus nuclear antigens (EBNA) 2--6, and the two latent 
membrane proteins  1  and  2  that  are  expressed  in latendy 
infected cells  (for a review see reference  15).  Several pep- 
tide epitopes have been identified in the primary sequences 
of these viral products, each recognized in the context of a 
specific class I allele.  Thus,  an individual's class I genotype 
strongly influences EBV-specific responses both in terms of 
antigen choice and quantitatively, in that strong CTL reac- 
tions are frequently restricted through certain class I alleles. 
HLA All  provides  a  clear  example  of the  phenomenon 
since effectors restricted through this determinant are usually 
the major component of polyclonal CTL cultures from All- 
positive Caucasians  (19,  20).  We previously identified  five 
All-restricted  CTL  epitopes  within  residues  101-115, 
396-410,  416-429,  481-495,  and  551-564  of  the  viral 
EBNA4  protein  (21),  and  mapped  the  minimal  cognate 
peptides  of two of these  epitopes within EBNA4 residues 
416-424  (IVTDFSVIK,  designated  IVT)  and  399-408 
(AVFDRKSDAK, designated AVF)  (20,  21).  Screening of 
polyclonal  CTL  cultures  for  pepfide-specific  reactivities 
demonstrated in all cases strong recognition of IVT and fig- 
nificantly  weaker  responses  to  AVF,  whereas  reactivities 
against other epitopes either tended to be lost on serial pas- 
sages  or,  with  some  of the  donors,  were  never  detected. 
The possibility that such a hierarchy of responses may re- 
flect differences in the immunogenicity of the epitopes was 
substantiated by the finding that mutations within the  an- 
chor residues  of the IVT peptide  abrogated CTL recogni- 
tion  in  a  series  of 33  EBV  isolates  from  Southeast  Asia, 
where HLA All  is expressed in >50% of the population, 
whereas only half of the isolates carried concomitant muta- 
tions within the AVF peptide (20). Thus, CTL responses to 
IVT appear to exert a stronger selective pressure in vivo. 
We  have  now investigated  the  molecular basis  for the 
different  immunogenicity  of the  IVT and  AVF epitopes. 
We  report  that  a  strong  predominance  of IVT-specific 
CTL clones in polyclonal cultures derived from autologous 
LCL stimulation correlates with a more efficient presenta- 
tion at the surface of All-positive LCLs and with a higher 
abundance of the peptide in acid extracts of virus-infected 
cells.  Analyses of TAP-dependent translocation,  All-pep- 
tide complex stabihty in cell lysates, and turnover in meta- 
bohcally active cells indicate that efficient antigen presenta- 
tion  and  immunodominance  may be  accounted  for by  a 
longer life span of IVT-containing molecules at the surface 
of APCs. 
Materials and Methods 
Cell Lines.  B95.8 EBV-transformed LCLs were obtained by 
infection oflymphocytes from HLA class l-typed donors with cul- 
ture supernatants  of the virus producer B95.8 hne (22) and are in- 
dicated in the text by the initials of the donor followed by a B, for 
B95.8, and a number corresponding to the transformation experi- 
ment from which the cell line was derived. All cell lines were main- 
tained in tkPMI 1640 supplemented with 100 ~g/ml streptomy- 
cin, 100 IU/ml penicillin,  and 10% FCS (complete medium). 
Synthetic Peptides.  Peptides,  synthesized by the Merrifield  solid 
phase method (23), were purchased from Alta Bioscience (The Uni- 
versity of  Birmingham, School of  Biochemistry, Birmingham, UK). 
The peptides were dissolved in DMSO at a concentration of 10 -2 
M  and were further diluted in PBS to obtain the indicated con- 
centrations  before the assays. The protein  concentration of the 
DMSO stock solutions was determined by a Biuret assay (24). 
Expression of EBNA4.  Aliquots of 107 cells were dissolved in 
1 ml electrophoresis sample buffer and sonicated.  100 p,1 of  the total 
cell extracts was separated by discontinuous 7.5% polyacrylamide- 
SDS  gel  electrophoresis  according to  the  method  of Laemmli 
(25), and blotted onto nitrocellulose  filters (26). The efficiency of 
the protein transfer and the position of molecular weight markers 
were visualized by staining with Ponceau-S (Sigma Chemical Co., 
St. Louis, MO). Excess protein binding sites were blocked by in- 
cubation for 1 h in PBS containing 5% dried skim milk and 0.1% 
Tween 20. The filters were subsequently incubated with a 1 : 50 
dilution  of a previously characterized human serum HR.  (vical 
capsid  antigen,  1:5,120;  EBNAI,  1:320;  EBNA2A,  1:640; 
EBNA2B,  1:40; and EBNA6,  1:640)  in PBS-milk for 2  h  at 
room temperature or for 16 h at 4~  After three washes in PBS- 
milk, the filters were incubated with horseradish peroxidase--con- 
jugated goat anti-human antibodies,  and the reaction was visual- 
ized by enhanced chemiluminescence  (Amersham International, 
Amersham, Bucks, UK) according to the manufacturer's instruc- 
tions.  The intensity of the EBNA4-specific band was measured 
by densitometry using a laser spectrophotometer (LKB, Brornma, 
Sweden) equipped with a scanning attachment. 
Natural Peptide Extraction and Fractionation.  Cultured cells were 
harvested  by centrifugation, washed in cold PBS, and stored in 
batches  of 109 at -70~  Cell pellets were lysed by adding 10 m] 
0.7% aqueous TFA on ice,  homogenized in a Dounce homoge- 
nizer (Kontes,  Vineland,  NJ) with 50 strokes,  and sonicated with 
3 ￿  15-s bursts; additional TFA was added to bring the pH of the 
lysate below 2. The material  was transferred  to a Centriprep  10 
ultracentrifugation device (Amicon, Beverly, MA) and subjected 
to centrifugation at 2,600 g for 3-5 h at 4~  until the volume of 
retained  fraction was  ,'-,1 ml.  The  ultrafiltrate  (molecular  mass 
<10  kD)  was  fractionated by HPLC  using  the  conditions  de- 
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of ultrafdtrate was loaded on SuperPac  TM  Pep-S 5p, reverse phase 
column  (Pharmacia, Uppsala,  Sweden).  Unbound  material was 
eluted with 100% solvent A (0.1% TFA in H20  ) until the optical 
density of the flow through had reached baseline levels. Bound 
material was eluted on a linear gradient of 1.5% B/min at a flow 
rate of I  ml/min where B  =  0.1% TFA in acetonitrile. 40 frac- 
tions were collected at  l-rain intervals in siliconized microfuge 
tubes, dried by SpeedVac (Pharmacia) and redissolved in 300/xl 
of PBS with vortexing. 
Peptide Translocation Assays.  Streptolysin-O-mediated transport 
assays were performed as described by Neefjes et al.  (27) using a 
125I-labeled synthetic peptide library constructed from the refer- 
ence TYNTRALI peptide with fixed amino acids to allow iodi- 
nation (Y) and glycosylation (N and T) (13).  The peptide library 
was labeled by chloramine T-catalyzed iodination to  a specific 
activity of 10  Ci/mmol. Briefly, 106 LCL cells were permeabi- 
lized with 2 IU/rnl streptolysin-O (Wellcome Diagnostics, Dart- 
ford, UK) for 10 rain at 37~  Iodinated peptide library (,~66 ng) 
was added and incubation was continued for 10 min in the pres- 
ence or absence of 10 mM ATP (Sigma Chemical Co.). The cells 
were then transferred to ice, lysed in buffer containing 1% NP-40, 
150  mM NaC1,  5 mM MgC12, and 50 mM  Tris-HC1, pH 7.5, 
and nuclei were removed by microcentrifugation at 14,000 rpm 
for 10 re.in. Translocated peptides which had been glycosylated in 
the ER. were recovered by absorption to Con A-Sepharose beads 
(Pharmacia). The beads were washed five times in lysis buffer and 
the  associated radioactivity was  measured in  a  gamma  counter 
(LKB, Uppsah, Sweden). Competition experiments were performed 
by mixing the indicated amounts of IVT or AVF peptides with 
the iodinated peptide library before addition to the streptolysin-O 
permeabilized cells. 
Stability and Turnover of HLA A 11-Peptide Complexes.  The  T2/ 
A11 cell line, obtained by transfection of  the transporter-deficient 
mutant T2 cell line (28) with a pHEBO vector-based HLA A11 
expression vector  (29),  was  maintained in  medium  containing 
200  I.Lg/ml hygromicin-B.  "Empty"  and peptide-loaded class I 
molecules were induced by culturing aliquots of 107 cells over- 
night at 26~  in serum-free AIM-V  ~  medium  (GIBCO BRL, 
Gaithersburg, MD) alone or medium containing 10 -6 M  oflVT 
or AVF peptide. After extensive washing to remove the unbound 
peptides, surface 125I labeling was performed by the lactoperoxi- 
dase method. The temperature stability ofiodinated class I mole- 
cules was assessed by incubating lysates of 106-labeled cells at the 
indicated temperature for 2 h  or at 37~  for the indicated time 
before iinmunoprecipitation with the W6/32 mouse mAb (30). 
The pH sensitivity was assessed by preincubating 106  iodinated 
cells for 2 h at 4~  in 500 Ixl of buffer at the indicated pH before 
lysis. The immunoprecipitated complexes were resolved by SDS- 
PAGE and the specific class I heavy chain and 132-microglobulin 
(132m) bands were visualized and quantitated by phosphoimager 
scanning. To determine the turnover of A11-peptide complexes 
at the surface of live cells, aliquots of 107 T2/A11 cells were met- 
abolically labeled by overnight culture at 26~  in methionine- 
free  RPMI  1640  medium  containing  100  p,  Ci[3SS]methionine 
and 1% FCS with or without addition of 106 M  of the AVF or 
IVT peptides. The cells were then washed five times in PBS, re- 
suspended in complete medium at a concentration of 0.5  ￿  106 
ml, and cultured at 37~  Allquots were harvested at the indicated 
times, washed in PBS, and incubated for 1 h at 4~  with 2  Ixl of 
W6/32  ascites.  After extensive washes to remove the unbound 
antibodies, the cells were lysed in 1 ml IEF lysis buffer as previ- 
ously described (31).  HLA class I-W6/32 complexes were pre- 
cipitated from the cell lysates by 2)< incubation with 50 p,l of a 
10%  suspension  of formalin-fixed Staphylococcus aureus  (Sigma 
Chemical Co.), and the immunoprecipitates were digested for 2 h 
at 37~  with neuroaminidase (Sigma type VIII) at a concentra- 
tion of 10 U/ml in a volume of 20 gal. The class I polypeptides 
were resolved by 1D-IEF and detected by autoradiography (31). 
The  intensities of the 132m and class I  heavy chain bands were 
quantitated  by  densitometry from  suitably exposed  autoradio- 
grams. 
Generation of CTL Cultures and Clones.  EBV-specific CTLs were 
obtained as previously described (32) by stimulation of lympho- 
cytes from the EBV-seropositive donors BK (HLA A2,  11, B7, 
35) with the autologous B95.8 virus-transformed LCL. After two 
or three consecutive restimulations, the cultures were expanded 
in complete medium supplemented with  10 U/m/recombinant 
IL-2 and 30% (vol/vol) culture supernatant from the gibbon lym- 
phoma line MLA144 (33). Single cell cloning was done by limit- 
ing dilution in 96-well plates in 200 ~1 medium containing 30% 
MLA144 culture supernatant, 10 U/ml human recombinant IL-2, 
and  105  irradiated (3,000  tad)  allogeneic PHA-pulsed PBLs  as 
feeder. Growing cultures were transferred into 24-well plates and 
were fed twice a week by replacing half of the medium without 
any further stimulation. The EBV specificity  and class I restriction 
were investigated by testing the cytotoxic activity against a panel 
of EBV-positive and -negative targets, including the autologous 
LCLs, allogeneic LCLs matched through single class I alleles,  at 
least two  cell lines for each allele, PHA-activated blasts,  HLA- 
mismatched LCLs, and the prototype NK-sensitive target K562. 
Cytotoxicity Tests.  Cytotoxic activity was measured in standard 
4-h 51Cr release assays (32). The targets were hbeled with Naslcro4 
(0.1  ~Ci/106 cells) for 1 h  at 37~  The cytotoxicity tests were 
routinely run at 10:1,  3:1, and 1 : 1 E/T ratios in triplicate. Pep- 
tide titration, competition assays, and tests of HPLC fractions were 
performed by adding 20 I.d of the peptide preparations to 4 ￿  103 
labeled targets (in 20 ~1 complete medium) in triplicate wells of 
96  V-shaped well plates. The plates were incubated for  1 h  at 
37~  before  addition  of  the  CTLs.  Peptide  toxicities  were 
checked in each assay and were always --<3%. In all other assays, 
peptide pulsing was performed by incubating the targets in the 
presence of 10 -9 M ofpeptide during labeling followed by exten- 
sive washing before the cytotoxicity tests. 
Results 
IVT-specific CTLs Dominate HLA A 11-restncted  Responses  to 
EBNA4.  We  have  previously  observed  that  polyclonal 
HLA A11-restricted CTL responses to EBNA4  are domi- 
nated by reactivities to  the  nonamer peptide IVT,  corre- 
sponding to  residues 416-424  of the prototype B95.8  se- 
quence,  whereas  a  weaker  response  is  usually  detected 
against the  10-mer AVF derived from amino acid residues 
399-408  (21).  We  have  now  examined  this  issue  at  the 
clonal  level  and  have  compared  the  frequencies  of CTL 
clones specific for the AVF and IVT peptides in polyclonal 
cultures  obtained by stimulation of lymphocytes from  the 
All-positive donor BK  with  the  autologous B95.8  virus- 
transformed  LCL.  A  compilation  of the  results  obtained 
from the analysis of 173 clones derived from four CTL re- 
activation experiments performed over a period of 30 mo is 
shown  in  Table  1.  85%  of the clones  (146/173)  lysed the 
autologous  stimulator  LCL,  and  the  majority  (135/146, 
917  Levitsky et al. Table 1.  Spedfidty  of CTL Clones Generated by Autologous 
LCL Stimulation of Lymphocytes  fiom Donor BK 
Peptide 
HLA restriction  specificity 
No. of  Cytotoxic 
Expt.  clones  clones  All  Other  IVT  AVF 
1  32  25  23  2*  22  1 
2  19  16  14  2  13  1 
3  59  59  55  4  46  9 
4  63  46  43  3  28  15 
Tot~  173  146/173  135/146  11/146  109/135  26/135 
(%)  (85)  (92)  (8)  (81)  (19) 
A 
B 
100 
.~_  80 
--~  60_ 
0 
0  40. 
e~ 
20. 
100- 
i VT 
"~O--  AVF 
,  ,  ￿9  ,  ,  ,  .  ,  ,  ,  ￿9  ,  ￿9  , 
7  8  9  10  "11  12  13 
Peptide concentration [-IogM] 
Polyclonal CTL  cultures from  donor BK (HLA A2, All B7,  B62) 
were cloned by limiting dilution. The specificity of the derived clones 
was assessed  on a panel of targets including the autologous LCL and al- 
logeneic  All-matched or-mismatched  LCLs. All-restricted clones 
were further tested for lysis of All-matched PHA blasts preincubated 
with 10  -9 M of the IVT or AVF peptides. 
*EBV-specific CTL clones restricted through other class I alleles  ex- 
pressed i  n the donor and nonspecific CTL clones that lysed class I-mis- 
matched LCLs and the prototype NK-sensitive target K562. 
93%) were EBV specific and A11 restricted in that they lysed 
aUogeneic All-matched LCLs,  but not All-positive PHA 
blasts, mismatched LCLs,  or LCls matched  through  other 
class I  specificities. Only 8%  of the  cytotoxic clones  (11/ 
146) were either EBV specific and restricted through other 
class  I  alleles expressed in  the  donor,  or  exhibited LAK- 
type cytotoxicity. In accordance with  the results obtained 
with  polyclonal cultures,  the All-restricted response  was 
strongly  dominated  by  CTL  clones  specific  for  the  IVT 
epitope  (109/135,  81%)  whereas  only  19%  of the  clones 
(26/135)  recognized the AVF epitope. 
Wide variations have  been  reported in the  amounts  of 
synthetic peptides required to trigger lysis by different CTL 
clones, probably reflecting differences in the avidity of their 
TCRs.  We have  therefore compared IVT- and AVF-spe- 
cific CTLs for their capacity to lyse PHA blasts in peptide 
titration assays. As illustrated in Fig. 1 A, where target sen- 
sitization was tested across a  10 -7 to 10 -12 M  range of pep- 
tide concentrations, both peptides were active down to pi- 
comolar concentrations, reaching half-maximal lysis points 
at  5  ￿  10 -l~ M.  Similar dose-response  curves  were  ob- 
tained in experiments performed with more than 10 indivi- 
dual IVT- and AVF-specific clones (not shown).  We then 
compared lysis of blasts pulsed with 10 -9 M  of the relevant 
peptide for lysis by  IVT-  and  AVF-specific CTLs  over a 
wide range of E/T  ratios (Fig. 1 B). Equal levels of killing 
were observed at all ratios, confirming the similar efficiency 
of the effectors. 
The  IVT Epitope  Is  Presented  More  Efficiently  than A VF. 
During the course of the above screening a  consistent dif- 
ference  was  observed in  the  capacity of AVF-  and  IVT- 
specific  CTLs  to  lyse  different  types  of targets.  Whereas 
peptide-pulsed blasts were lysed equally well, A11-positive 
80- 
60. 
0 
q,. 
O  40- 
~  20- 
O- 
IVT 
IVT  +pep 
AVF 
AVF  +pep 
50  12.5  3.1  0.8  0.2  0.05 
effector:target  ratio 
Figure  1.  CTL  clones specific for the  IVT  and AVF epitopes lyse 
equally well PHA blasts pulsed with synthetic peptides. (A) HLA A11- 
positive PHA blasts were preincubated for 1 h with  10-fold serial dilu- 
tions of the IVT or AVF peptides and were then used as targets for the 
AVF-specific CTL  clones BK280 (open symbols) or IVT-specific CTL 
clones BK102 (closed  symbols). The percent specific  lysis recorded at a 10: 
1 E/T ratio in one representative experiment out of three is shown. (/3) 
Untreated (circles) and peptide-pulsed (squares) blasts were tested for sensi- 
tivity to lysis by the IVT-specific clone BK289 (filled symbols) and AVF- 
specific clone BK280 (open symbols) in standard 4-h S~Cr release assays. 
The targets  were preincubated with 10 -9 M of  the indicated peptide for 1 h 
during labeling and extensively washed to remove unbound peptides be- 
fore the assays. One representative experiment out of three is shown. 
LCLs were  regularly more sensitive to  IVT-specific cyto- 
toxicity. A  compilation of the  mean percent specific lysis 
recorded at a  10:1  E/T  ratio in at least 3  and up to 10 in- 
dependent experiments performed with a panel of 12 B95.8 
virus-transformed  LCLs  from  All-positive individuals  is 
shown in Fig. 2 A. Reproducible levels of killing were ob- 
tained in experiments performed with  each cell line using 
different  IVT-  and  AVF-specific clones.  All LCLs  tested 
were  lysed more  efficiently by the  IVT-specific effectors, 
although significant differences in the levels of killing were 
detected with individual cell lines. 
To assess whether these differences could be ascribed to 
variations in the levels of endogenous EBNA4  expression, 
this  parameter  was  measured  in  parallel with  IVT-  and 
AVF-specific killing in a representative panel of seven A 11- 
positive LCLs. EBNA4 expression was quantitated by den- 
sitometry in  immunoblots  of total  extracts from  106  cells 
probed with a previously characterized human serum con- 
taining high antibody titers to all EBNAs.  Similar levels of 
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over a  broad range of E/T  ratios.  Representative experi- 
ments, where the IVT-specific clone BK289 and AVF-spe- 
cific clone BK280 were titrated by twofold dilutions against 
a fixed number of targets, are shown in Fig. 3. Equal levels 
of IVT- and AVF-specific killing were observed with pep- 
tide-pulsed targets over E/T ratios ranging from 50 : 1 down 
to 0.025 : 1. In contrast, untreated LCLs remained less sen- 
sitive to AVF-specific lysis even at E/T ratios as high as 50 : 1. 
It is noteworthy that plateau levels ofkiUing were achieved 
against all targets with E/T  ratios significantly lower than 
50 : 1, confirming that the effectors were not limiting in the 
assays.  Because the dose-response curves of the IVT- and 
AVF-specific CTLs  were  identical against peptide-pulsed 
targets, discrepancies in their activity against untreated cells 
are probably due to differences in the efficiency of presen- 
tation of the  epitopes.  Thus, presentation of the  endoge- 
nous AVF epitope varied in different cell lines between 20 
and 30% of that required to trigger maximal lysis achieved 
with peptide-pulsed cells, whereas presentation of the en- 
dogenous IVT epitope was between 60 and 80%. The un- 
equal presentation of these determinants is likely to reflect 
the relative abundance of the corresponding class I-peptide 
complexes in virus-infected cells and may be influenced by 
selective  peptide  transport,  differences  in  the  affinity  of 
binding, or unequal persistence of the complexes in APCs. 
Figure 2.  HLA All-positive LCLs are lysed more efficiendy  by IVT- 
specific effectors independendy of the endogenous levels of EBNA4 ex- 
pression. B95.8 virus-transformed  LCLs from the HLA All-positive in- 
dividuals SW (All, A24, B44, B55); GD (A2, All, B35, B41); KK (All, 
A28, B14, B40);  JAC (A1, All, B49, B55); IARC 171 (All, A32, B35, 
B49); IE (A3, A11, B7, B35); BK (A2, All, B7, B62); QYY (A2, A22, 
B13, B38); LF (A2, All, B7, B37); QJZ (All, B13, B51); and TD (A2, 
All, B44, B55) were tested for sensitivity  to lysis by the IVT-specific 
clones BK102, BIC263, and BK250 (closed symbols)  and AVF-specific 
clones BK248, BK280, and BK203 (open symbols).  Each symbol corre- 
sponds to the mean + SE of the percent specific lysis recorded at a 10:1 
E/T ratio in at least three experiments  performed with each E/T combi- 
nation. (B) Protein extracts from total cells  were separated by SDS-PAGE 
and immunoblots  were probed with a previously  characterized human se- 
rum with  high antibody titers to  all EBNAs (HR:  VCA, 1:5,120; 
EBNA1, 1 :  320; EBNA2A, 1 : 640; EBNA2B, 1 : 40; and EBNA6, 1 : 640). 
The EBNA4-specific  band was identified by comparison  with the B95.8 
reference cell line and the intensity  was quantitated  by densitometry.  The 
results of one representative  experiment out of three where EBNA4 ex- 
pression and sensitivity  to AVF (open circles) and IVT-specific  lysis (closed 
circles) were tested in parallel  are shown. 
expression were  detected on repeated testing of the same 
LCL, but wide variations were observed when the intensity 
of the  EBNA4-specific  band  was  compared  in  different 
LCLs. As illustrated by the representative experiment shown 
in Fig. 2  B, there was no correlation between the level of 
EBNA4  expression and the  sensitivity to  AVF- or  IVT- 
specific cytotoxicity. All cell lines were lysed poorly by the 
AVF-specific effector in spite of greater than 10-fold differ- 
ences in the expression of EBNA4. 
To  explore  this  phenomenon further,  untreated  and 
peptide-pulsed LCLs were compared for sensitivity to lysis 
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Figure 3.  The endogenous IVT and AVF epitopes are presented with 
different efficiency  at the surface of HLA All-positive LCLs. Untreated 
(drdes) and peptide-pulsed (squares) LCL cells were tested for sensitivity  to 
lysis by the IVT-specific  clone BK289 ~fitted symbols)  and AVF-specific 
clone BK280 (open symbols) in standard  4-h 51Cr release assays. The targets 
were preincubated with 10  -9 M of the indicated peptide for 1 h during 
labeling  and extensively  washed to remove unbound peptides before the 
assays. One representative  experiment out of three is shown. 
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LCLs and in the  TAP-deficient mutant T2/A11  transfec- 
tant. 
Abundance of Naturally Processed IVT and A VF Peptides  in 
LCL Cells.  Cytosolic peptides are rapidly degraded unless 
they  are  protected  by  binding  to  class  I  molecules  (34). 
Thus,  the  recovery of peptides  from acid extracts  of total 
cell lysates can be taken as a good correlate of the amount 
of complexes  present  in  a  given  cell.  To  determine  the 
abundance  of class  I  molecules  containing  the  naturally 
processed IVT and AVF peptides, A11-positive LCLs were 
expanded  and  the  MHC-bound  peptides  from  109  cells 
were isolated by TFA extraction, ultrafiltration,  and reverse 
phase  HPLC fractionation.  As control,  peptides  were  ex- 
tracted under the same conditions from A11-negative LCLs 
and from EBV-negative A11-positive or -negative BL lines 
and PHA blasts.  As illustrated in the representative  experi- 
ments  shown in  Fig.  4,  HPLC fractions from EBV-nega- 
tive  ceils  did  not  sensitize  All-positive  blasts  to  lysis  by 
AVF-  or IVT-specific  effectors  (Fig.  4  A).  When  HPLC 
fractions from A11-positive LCLs were tested in cytotoxic- 
ity assays,  a peak of AVF-specific reactivity was recovered 
in fractions 15 and  16, whereas IVT-specific reactivity was 
detected in fractions 23 and 24 and occasionally fraction 22 
(Fig.  4  B).  The retention  times  of the  naturally processed 
peptides were identical to those observed in spiking experi- 
ments where 100 pg of synthetic IVT and AVF peptides were 
added to 109 EBV-negative ceils immediately before extrac- 
tion  and  fractionation  (Fig.  4  C).  Similar  retention  times 
were also observed when synthetic IVT and AVF peptides 
were fractionated according to the same HPLC conditions 
(not shown).  To estimate  the  abundance  of naturally pro- 
cessed peptides,  the active HPLC fractions were titrated in 
cytotoxicity assays  and the percent  specific lysis  was  com- 
pared with standard curves from cytotoxicity assays carried 
out under the same conditions with synthetic peptides (Fig. 
5). A compilation of the estimated content oflVT and AVF 
in A11-positive  and  -negative LCLs and in control EBV- 
negative cells  is shown in Table 2. IVT- and AVF-specific 
reactivities were regularly detected in peptide extracts from 
A11-positive LCLs, only in some extracts from A11-nega- 
tive LCLs, and in none of the extracts from EBV-negative 
cells.  Empty runs  tested  before  each peptide  fractionation 
were always negative, confirming that no cross-contamina- 
tion had occurred between runs.  The recovery of peptides 
varied considerably between different ceil lines,  but similar 
levels  were  detected  in  repeated  experiments  performed 
with the same cell line.  The recovery of IVT peptides was 
in each case higher than the AVF recovery with calculated 
abundances  ranging  between  about  350  and  12,800  and 
about 8 and 760 molecules per ceil, respectively. The per- 
cent specific lysis induced by the active fractions from three 
spiking experiments with known amounts of synthetic pep- 
tides corresponded to an average efficiency of recovery of 
~30%  for  both  AVF  and  IVT  (Fig.  4  C,  and  data  not 
shown),  confirming  that  higher  yield  of IVT  in  extracts 
from EBV-positive  ceils  is not an artefact  of the  fraction- 
ation procedure. 
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Figure 4.  Isolation of naturally processed IVT and AVF peptides from 
EBV transformed LCLs. 109 cells from the HLA All-positive EBV-neg- 
ative line BL28 (A), the HLA All-positive LCL BK-B4 (B), or BL28 
cells spiked with 10 pg IVT and AVF peptides (C) were lysed in 1% TFA, 
homogenized with a Dounce homogenizer, subjected to ultrafiltration in 
order to isolate peptide containing fractions (<10 kD), and fractionated 
by C18 HPLC using a gradient of 1.5% acetonitrile/min at a flow rate of 
1 ml/min. Fractions were collected at l-rain  intervals, dried, and tested 
for their ability to sensitive HLA A11-positive PHA blasts to lysis by the 
IVT-specific clone BKl12 (filled symbols) and AVF-specific  clone BK280 
(open symbols) in standard 4-h SlCr release assays. Toxicity controls con- 
sisting of target cells incubated in the absence of CTLs were negative (not 
shown). 
TAP-dependent  Transport.  Differences  in  the  efficiency 
of TAP-dependent translocation to the site of class I assembly 
could  result  in  preferential  formation  of IVT-containing 
complexes.  We  compared,  therefore,  the  capacity of syn- 
thetic IVT and AVF peptides to compete the transport of a 
reference  peptide  library  in  streptolysin-O  permeabilized 
LCL cells.  A  125I-labeled  peptide  library,  containing 2,304 
peptides  with  variable  COOH  termini  was  used  to  assess 
TAP-  and  ATP-dependent  translocation  by  virtue  of 
N-linked  glycosylation and consequent retention in the ER 
lumen  (13).  Translocation  of the peptide library was com- 
peted by addition of cold IVT or AVF peptides in a dose- 
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Figure 5.  Calculation ofpeptide recovery. 109JL-B1 (HLA All, A28, 
B35, B44) cells were fractionated as described in Fig. 4. The active HPLC 
fractions recognized by BK298 (fractions 23 and 24) and BK280 (fractions 
15 and 16) CTL were tit'rated in standard cytotoxicity assays using HLA 
All-positive blasts as targets. The percent specific lysis values obtained 
using 5 ￿  107 cells equivalent per well (i.e., 5% of the active fraction) are 
plotted on titration curves performed with known  amounts of synthetic 
IVT or AVF peptides in the same assays. The estimated content of IVT 
peptide was 49 fmol in fraction 23 and 22 fmol in fraction 24, and the 
content ofAVF peptide was 4.5 fmol in fraction 15 and 5.5 fmol in frac- 
tion  16. This corresponds to a calculated recovery of ~1,050  IVT and 
~200 AVF molecules perJL-B1 cells. 
dependent  manner  (Fig.  6).  Similar dose-response  curves 
were obtained with the two peptides, indicating that there 
is no  selective transport into  the EK/pre-Golgi compart- 
ment. 
The  IVT  and A VF Peptides  Bind  Equally  Well  to  HLA 
A 11.  We next examined whether the higher abundance 
of [VT could be ascribed to differences in the ability of the 
peptides to associate with A11 or in the stability of the cor- 
responding complexes. First, the capacity of synthetic IVT 
and  AVF  to  reciprocally inhibit  T  cell  recognition  was 
tested in functional assays using specific CTLs as reporters 
of A11-peptide association. HLA A11-positive blasts were 
pulsed for 1 h  at room temperature with a mixture of 10 -9 
M  of the reporter peptide and graded concentrations of the 
competitor peptide to estimate the concentration required 
for 50% inhibition of CTL responses (Fig. 7). In several in- 
dependent  experiments,  equal  concentrations  of competi- 
tor peptide were  required  to  inhibit IVT-  and AVF-spe- 
cific lysis. Thus, rxvl0  -6 M  oflVT  peptide was required for 
50% inhibition of cytotoxicity induced by 10 -9 M  of AVF 
and vice versa, suggesting that peptides have a similar affin- 
ity for A11 molecules. 
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Table 2.  Estimated Content of lVT and A VF Peptides 
No. of 
Cell type  experiments 
Peptide 
molecules/ceU 
IVT  AVF 
EBV + HLA Al1 +* 
EA-B 1  4  l 2,800*  760 
SI-B1  1  35O  8 
JL-B1  1  1,050  200 
LF-B1  1  1,300  nt 
BK-B4  3  10,000  10' 
EBV + HLA All- 
GK-B2  1  263  119 
JM-B2  1  550  nt 
LS-B 1  1  < 1  nt 
SN-B 1  1  < 1  nt 
EBV- 
BK PHA blasts  1  < 1  < 1 
BJAB  3  < 1  < 1 
BL28  1  < 1  < 1 
*Peptide  recovery was calculated for each separation as described in 
Fig. 5. The values represent the estimated recovery of individual sepa- 
ration  experiments  or the average of repeated  separations performed 
with each cell hne. 
J; AVF recovery was calculataed only in one of the three experiments. 
nt, not tested. 
The relative stability of A11-peptide complexes was esti- 
mated by measuring their rate  of dissociation in lysates of 
surface-iodinated T2/A11  cells as  a  function  of tempera- 
ture, time at 37~  and pH. All  molecules loaded with the 
IVT  or AVF peptide were  induced at the surface of T2/ 
All  cells by  overnight  incubation  at  26~  in  serum-free 
medium containing 10 -6 M  of synthetic peptides. After ex- 
tensive washes to remove the unbound peptides and surface 
iodination, lysates of 106 cells were incubated at increasing 
temperature  for  2  h,  or  at  37~  for  different periods  of 
time.  Class  I  molecules  were  then  precipitated with  the 
W6/32  mAb  and  resolved  by  SDS-PAGE.  As  expected, 
class I molecules induced by incubation of T2/A11  cells in 
the  absence of exogenous  peptides were  unstable  at tem- 
peratures higher than 25~  (Fig. 8 A). In contrast, the ma- 
jority of molecules induced by incubation in the presence 
of both  IVT  and  AVF  peptides  was  stable  at  37~  and 
42~  with  recoveries varying between  70  and 90  and  50 
and 70% of that observed at 25~  respectively. Virtually all 
complexes were disrupted after incubation for 2  h  at 50~ 
Comparable  dissociation kinetics  of IVT-  and  AVF-con- 
taining complexes were also demonstrated after incubation 
at 37~  for prolonged periods of time  (Fig. 8  B).  To  test 
the stability of the complexes as a function ofpH, iodinated 
T2/All  cells were  preincubated for 2  h  at 4~  in citrate r 
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Figure 6.  The [VT and AVF peptides compete equally well for TAP- 
dependent translocation.  106 BK-B4 cells were permeabilized with 2 IU/ 
ml streptolysin-O for 10 rain at 37~  and further incubated for 10 min 
with the iodinated peptide library with (open triangle) or without (filled tri- 
angle) addition of 10 mM ATP. Translocated peptides that had been gly- 
cosylated in the ER were recovered by absorption to Con A-Sepharose 
beads and the radioactivity  was measured in a gamma counter. The indi- 
cated amounts of synthetic IVT (flied symbols)  or AVF peptides (open sym- 
bols) were mixed with the iodinated peptide library before addition to the 
streptolysin-O permeabihzed cells. One representative experiment out of 
three is shown. 
phosphate buffers of pH ranging from 7  to  4  before lysis 
and immunoprecipitation with the W6/32 mAb (Fig. 8 C). 
Class I molecules induced in T2/A11 cells in the absence of 
exogenous peptides were unstable  at pH higher than  5.5, 
whereas both IVT- and AVF-containing  complexes were 
unaffected at pH 4.5 and N20% of the complexes was still 
detectable a~er incubation at pH 4. 
Rapid  Turnover of A VF-containing  Complexes  in Metaboli- 
cally Active Cells.  In the final set of experiments,  the  life 
span  of class  I  molecules  loaded  with  IVT  or  AVF  was 
compared in intact cells  incubated at 37~  T2/A11  cells 
were metabolically labeled overnight at 26~  either alone 
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Figure  7.  The IVT and AVF peptides compete equally well in target 
sensitization  assays. HLA All-positive blasts were preincubated for 1 h at 
room temperature in the assay well with a mixture of 10 -9 M of the IVT 
or AVF peptide and  the  indicated molar concentration of competitor 
peptide before addition of the IVT-specific clone BK289 or AVF-specific 
clone BK280  at  a  10:1  E/T  ratio.  (Closed  symbols)  AVF-specific  lysis 
competed by IVT peptide; (open symbols)  IVT-specific  lysis competed by 
AVF peptide. The percent IVT- and AVF-specific  lysis in the absence of 
competitor peptide was 61 and 47%, respectively.  One representative ex- 
periment out of three is shown. 
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Figure 8.  HLA At 1 molecules containing the IVT and AVF peptides 
are equally  stable over a wide range of temperature and pH conditions. 
Surface HLA A11 molecules were induced in T2/A11 cells by overnight 
incubation at 26~  in serum-ftee medium alone (open bars), medium con- 
taining 10 -6 M  IVT (flied bars), or AVF peptides  (hatched bars). After ex- 
tensive washes to remove the unbound peptides,  the cells were surface io- 
dinated.  The temperature stability  of class I  molecules was assessed by 
incubating lysates ofl06 cells at the indicated temperature for 2 h (A) or at 
37~  for the indicated time (B) before immunoprecipitation. (C) The pH 
sensitivity of the complexes was assessesd by preincubation of 106 labeled 
cells for 2 h at 4~  in 500 p,1 buffer at the indicated pH before lysis. Class 
I  molecules were  immunoprecipitated using the W6/32  mAb and the 
complexes were resolved by SDS-PAGE. The specific class I heavy chain 
and ~2m bands were visualized  and quantitated by phosphoimager scan- 
ning. One representative experiment out of three is shown. 
or in the presence of 10 -6 M  of the peptides. After exten- 
sive washes,  the  cells  were placed back in  medium alone 
and surface class I molecules were chased at 37~  for differ- 
ent times. As expected, A11  molecules induced in the ab- 
sence of exogenous peptides were rapidly cleared from the 
cell surface with an approximate half-hfe of 2.5 h  (Fig. 9, A 
and B).  The average half-life was prolonged for A11  mole- 
cules  induced in the presence  of peptides  but a  significant 
difference was observed in the life span of IVT-  and AVF- 
containing complexes (Fig. 9). Over 50% of the A11 mole- 
cules  containing AVF  had been  disrupted  after incubation 
at 37~  for 4  h  and only 20%  of the complexes were  still 
detected after 12 h,  corresponding to an approximate  half- 
life of 3.5  h.  In contrast,  after an initial decrease  observed 
during  the  first  4  h,  the  majority  of IVT-induced  com- 
plexes  remained stable with a  half-Ere exceeding the  12-h 
observation time. 
922  Immunogenicity and Lifespan of MHC Class I: Peptide Complexes Figure 9.  HLA A11 molecules containing the AVF peptide are rapidly cleared from the cell surface whereas IVT-containing complexes are stable. (A) 
T2/A11 cells were metabolically  labeled by culturing overnight at 26~  in methionine-free RPMI containing 100 ~Ci [3sS]methionine and 1% FCS ei- 
ther alone or in the presence of 10  -6 M IVT or AVF peptides. The cells were then washed five times in PBS to remove the excess of  unbound peptides, 
and incubated at 37~  in peptide-free medium for the indicated times. Precipitation of surface class I molecules and separation by 1D-IEF were per- 
formed as described in Materials and Methods. The specific class I heavy chain and B2m bands were identified by comparison  with a panel of previously 
characterized LCL of known HLA class I type. The HLA A2, B5, and B2m polypeptides, which are hardly visible in the figure, were clearly detected on 
longer exposures of  the autoradiograms. One representative experiment out of  four is shown. (B) The intensity of  the A11-specific  bands was quantitated 
by densitometry and the percent residual A11 was calculated as the ratio between the value observed at the indicated time after incubation at 37~  and 
the initial value. Shown is the mean result of  four experiments. 
Discussion 
The  question  of immunodominance  in  the  context  of 
class  I-restricted  CTL responses  to  intracellular  pathogens 
and  tumor  cells  has  attracted  considerable  attention  since 
immunodominant epitopes  are likely to elicit effective re- 
sponses in vivo and may therefore be preferential targets for 
immunization  or  passive  immunotherapy.  Very  little  is 
known  about  the  factors  influencing  immunodominance 
although,  in  different  model  systems,  correlations  have 
emerged  between  immunogenicity  and  the  chemistry  of 
peptide binding or the efficiency of antigen processing. We 
have now examined this issue with regard to human CTL 
responses  to  a  common herpesvirus,  EBV,  that  establishes 
life-long persistent  infections and is associated with a vari- 
ety of lymphoid and epithelial  cell malignancies.  We have 
shown that the relative immunogenicity of two HLA All- 
restricted  epitopes  derived  from  EBNA4  correlates  with 
the  efficiency of presentation  in  virus-infected  cells.  This 
parameter  appears  to be  strongly influenced by a  peptide- 
driven  persistence  of the  antigenic  complexes  at  the  cell 
surface. 
The possibility that the IVT epitope may be the immuno- 
dominant target of HLA All-restricted responses to EBV- 
infected  cells  in  vivo had been previously surmised  based 
on  the  reactivity  of polyclonal CTL  cultures  from EBV- 
immune donors and on the regular detection of mutations 
affecting this  peptide  in EBV isolates  from Southeast Asia 
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where HLA All  is expressed in more than 50% of the pop- 
ulation  (20).  We  have  now substantiated  this  assumption 
by  demonstrating  that  ~80%  of the  All-restricted  CTL 
clones reactivated by autologous LCL stimulation  of lym- 
phocytes from the EBV-immune donor BK are specific for 
this epitope, whereas only 20% of the clones recognize the 
subdominant  epitope  AVF.  A  similar pattern  of IVT pre- 
dominance was observed in four CTL reactivation experi- 
ments performed over a period of 30 mo and is therefore a 
stable feature of EBV-specific responses in this donor (Ta- 
ble  1). The significance of this finding was corroborated in 
less  extensive  screenings  performed  with  two  additional 
A11-positive individuals which also yielded a similar preva- 
lence of IVT-specific clones (Levitsky, V., unpublished re- 
suits).  Dose-response  experiments  performed  over a  wide 
range  of synthetic  peptide  concentrations  and  E/T  ratios 
confirmed that the differences cannot be ascribed to an in- 
trinsically  lower  efficiency  of the  AVF-specific  effectors 
which  could  have  hampered  the  expansion  of these  cells 
during in vitro restimulation  (Fig.  1).  It is noteworthy that 
comparable, albeit very low, frequencies of IVT- and AVF- 
specific  precursors  were  demonstrated  after  autologous 
LCL  stimulation  of lymphocytes  from  EBV-seronegative 
donors under limiting dilution  conditions  (Frisan,  T.,  and 
M.G.  Masucci,  unpublished  results).  Thus,  differences  in 
the relative immunogenicity of the IVT and AVF epitopes are unlikely to be due to obvious differences in the precur- 
sor T  cell repertoire. 
The  derivation  of IVT  and  AVF  from the  same  viral 
protein and restriction through the same class I allele,  to- 
gether with the similar efficiency of the specific CTL, al- 
lowed us to directly compare the presentation of the two 
determinants in EBV-infected cells.  Preferential killing by 
IVT-specific effectors was  demonstrated in  a  series  of 12 
LCLs derived from HLA All-positive individuals.  Equal 
sensitivity after pulsing with the relevant synthetic peptide 
indicates  that  lower  amounts  of AVF-containing  class  I 
molecules may be available  for CTL recognition at the sur- 
face  of untreated  cells  (Fig.  3).  To  address  this  issue  di- 
rectly, we applied the technique described by Falk et al. (3) 
to determine the abundance of naturally processed IVT and 
AVF  peptides  in  EBV-infected  cells.  From  the  titration 
curves of synthetic peptides we could estimate that a mini- 
mal recovery of one peptide per infected cell would be de- 
tected as a positive signal in target sensitization assays per- 
formed with HPLC fractionations from 109 cells, taking into 
account an efficiency of isolation of N30%. The abundance 
of naturally processed IVT peptides was  found to vary in 
different  cell  hnes  between  about  200  and  more  than 
12,000  molecules per cell,  whereas  the  recovery of AVF 
peptides was  10-20-fold lower on average (Figs.  4  and 5, 
and Table 2).  These estimated values are well within the 
range of those reported for other class I-restricted CTL tar- 
get epitopes derived from cellular proteins, e.g., between 
12,000  and  400,000  molecules per  cell for two  epitopes 
from the  enzyme c~-ketoglutarate recognized by alloreac- 
tive  CTLs  (35,  36),  viral antigens,  e.g.,  between  10  and 
1,500  molecules per cell of antigenic peptides from HIV 
and influenza virus antigens  (37,  38), or bacterial proteins, 
e.g.,  more  than  3,000  molecules  per  cell  of a  peptide 
epitope from Lysteria monocytogenes (39).  In contrast to the 
findings of Rammensee et al.  (34) that naturally processed 
peptides accumulate in detectable levels only in cell lines 
expressing the relevant class I molecules, we could demon- 
strate that IVT and AVF peptides are also in All-negative 
LCLs, albeit with relatively low abundance.  This discrep- 
ancy is probably explained by the fact that both GK andJM 
express the A24 and Aw68  alleles that belong to the All 
family. We have indeed observed that synthetic IVT and 
AVF stabihze the expression of  Aw68 in transfected T2 cells 
and AVF-pulsed, Aw68-positive targets are recognized by 
AVF-specific CTLs (Levitsky, V., unpubhshed results).  The 
large differences in the abundance  of IVT and AVF pep- 
tides in LCLs may be partially explained by experimental 
variations in the efficiency of recovery, although compara- 
ble  values  were  obtained  in  repeated  experiments  per- 
formed with the same cell line. Variations in the levels of 
expression of native antigens are likely to play a major role 
in  determining the  abundance  of the  processed product, 
but this cannot explain the different recovery of IVT and 
AVF  since  they are  derived from the  same  viral protein. 
We cannot rule out the possibility that differences in gen- 
eration of individual peptides by proteolytic degradation of 
EBNA4 may contribute to our findings. Indeed, preferen- 
tial processing was suggested to underlie the different im- 
munogenicity of two H-2Kb-restricted epitopes in chicken 
albumin (8). Whereas experiments addressing this question 
in the context of  EBNA4-specific responses are presently in 
progress, it is important to stress that the relationship be- 
tween IVT and AVF presentation was maintained over a 
more than  10-fold difference in  the level of endogenous 
EBNA4 expression (Fig. 2 B). Because the density of pep- 
tide epitopes at the cell surface is hkely to influence the af- 
finities of antigen-specific T  cell responses, our results pre- 
dict that TCR affinity will be higher in AVF-compared to 
IVT-specific  CTLs.  This  correlation was  in  fact demon- 
strated  in  CD8  blocking  experiments  performed  with  a 
large panel of CTL clones derived from four All-positive 
donors  (de  Campos-Lima,  P.O.,  V.  Levitsky, M.  Imzeh, 
and M.G. Masucci, manuscript in preparation). 
Numerous investigations have evaluated the contribution 
of class I binding affinity to epitope selection and immuno- 
dominance.  Positive correlations have been demonstrated 
using different biochemical methods including biosensor- 
based technologies that employ surface plasmon resonance 
to monitor binding of immobilized peptide to soluble class 
I  molecules  (10),  peptide  competitions with  radiolabeled 
standard peptide bound to detergent-solubilized class I (11, 
40), or peptide-driven association and dissociation rates  of 
soluble  class I-[32-m  complexes  (41-42).  Since  recombi- 
nant  All  molecules  are  not  available,  and  since we  also 
lack conformation-dependent mAbs that would selectively 
recognize A11-peptide complexes, our analysis of IVT and 
AVF  binding  affinity had  to  rely on  biologic  assays per- 
formed with live LCLs and A11-transfected, TAP-deficient 
mutants. We have shown that IVT and AVF peptides com- 
pete equally well for TAP- and ATP-dependent transloca- 
tion in streptolysin-O permeabilized cells (Fig. 6), suggest- 
ing that comparable amounts could be available  for loading 
into  nascent class I  molecules in vivo.  The  two peptides 
were also equally potent competitors in CTL target sensiti- 
zation assays (Fig. 7), indicating that they have similar affin- 
ities for All. In line with this observation is the finding that 
peptide-loaded  molecules  induced  at  the  surface  of T2/ 
All  cells by incubation at low temperature were equally 
stable in cell lysates exposed to a wide range of temperature 
and pH conditions (Fig.  8).  It is therefore very significant 
that AVF-induced complexes were rapidly cleared from the 
surface of T2/All  cells incubated at 37~  with a half-life 
only  shghtly  better  than  All  molecules  induced  at  low 
temperature  in  the  absence  of exogenous peptides.  This 
cannot be explained by a lower binding of the complexes 
to the mAb used for irnmunoprecipitation since W6/32 was 
used in all assays. 
Taken  together,  our  results  imply  that,  as  previously 
demonstrated for class II (43), peptides influence the repre- 
sentation of class I molecules at the surface of  APCs. Differ- 
ences  in  persistence  will  select for long-lived  complexes 
and are likely to affect both the potency and immunodom- 
inance of T  cell epitopes. The factors regulating such per- 
sistence are unknown. Conceivably, minor conformational 
changes could be sensed in live cells resulting in differential 
924  Immunogenicity and Lifespan of MHC Class I: Peptide Complexes handling  of the  complexes.  There  is  now  consistent  evi- 
dence suggesting that class I molecules recycle through the 
endocytic  compartment.  In the  study  of Reid  and  Watts 
(44),  "~2%  of the  surface  class  I  molecules  in  the  EBV- 
transformed A46 cell line were endocytosed over a period 
of I  rain and recycled to the cell surface with a half-life of 
about 2-3 rain.  Some complexes could be selectively lost 
during this extensive recycling because of a higher dissocia- 
tion  rate  in  the  endosomal  environment.  We  could  not 
demonstrate  any  significant  difference  in  the  stability  of 
IVT and AVF complexes at pH as low as 4.5 (Fig. 8  C), in- 
dicating  that  they  could  survive  equally  well  the  mildly 
acidic pH of the endosomes. Other factors may contribute, 
however, to a quality control in this cellular compartment, 
including the presence of some proteolytic enzymes (45). It 
is noteworthy that substitutions of solvent-exposed residues 
within  class  II-restricted peptide  epitopes  were  shown  to 
influence the half-life of the complexes without significant 
effect on binding affinity or peptide dissociation rates  (43). 
The findings presented in this paper have important impli- 
cations for the design ofpeptide-based vaccines and for the 
choice ofpeptide-specific CTLs for adoptive immunother- 
apy trials.  The  most efficient vaccines are likely be  those 
able to elicit CTL responses against antigenic epitopes that are 
efficiently expressed at the surface of  virus-infected or tumor 
cells.  The demonstration that this property is strongly de- 
pendent on the life span of the presenting class I molecules 
in live cells indicate that prediction of such epitopes cannot 
be reliably based on biochemical analysis of binding affinity 
or on the stability of isolated MHC-peptide  complexes. 
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